Assay Development for High Throughput Molecular Screening (R21)

The summary for the Assay Development for High Throughput Molecular Screening (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Assay Development for High Throughput Molecular Screening (R21): The purpose of this FOA is to facilitate the discovery of new molecular probes for investigating biological function by funding the development and adaptation of biological assays for automated high throughput molecular screening (HTS). This is one component of the NIH Molecular Libraries and Imaging Roadmap Initiative ( This Funding Opportunity Announcement (FOA) will utilize the R21 grant mechanism.
Federal Grant Title: Assay Development for High Throughput Molecular Screening (R21)
Federal Agency Name: National Institutes of Health
Grant Categories: Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-RM-07-001
Type of Funding: Grant
CFDA Numbers: 93.310
CFDA Descriptions: Trans-NIH Research Support
Current Application Deadline: No deadline provided
Original Application Deadline: Sep 23, 2006
Posted Date: Jul 13, 2006
Creation Date: Jul 13, 2006
Archive Date: Oct 23, 2006
Total Program Funding: $8,000,000
Maximum Federal Grant Award: $125,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
Special district governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education State governments For profit organizations other than small businesses Public and State controlled institutions of higher education Public housing authorities/Indian housing authorities Native American tribal governments (Federally recognized) City or township governments Small businesses Private institutions of higher education Independent school districts Native American tribal organizations (other than Federally recognized tribal governments) Others (see text field entitled "Additional Information on Eligibility" for clarification) County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Additional Information on Eligibility
Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Faith-based or community-based organizations can apply.
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants
Stimulating Peripheral Activity to Relieve Conditions (SPARC): Pre-clinical Development of...
Data Integration and Analysis Tools: Accessible Resources for Integration and Analysis of ...
Novel and Innovative Tools to Facilitate Identification, Tracking, Manipulation, and Analy...
Innovative Adaptations to Simplify Existing Technologies for Manipulation and Analysis of ...
Facile Methods and Technologies for Synthesis of Biomedically Relevant Carbohydrates (U01)
Using Metabolomics to Investigate Biological Pathways and Networks (R01)
Membrane Protein Production and Structure Determination (R01)
Solicitation of Assays for High Throughput Screening (HTS) in the Molecular Libraries Scre...
More Grants from the National Institutes of Health
Clarifying the Relationship between Delirium and Alzheimers Disease and Related Dementias ...
Multimorbidity in Alzheimers Disease Impacts Choice of Ancillary Treatments (R21/R33)
Pilot Clinical Trials in Pediatric Chronic Kidney Disease Participating Clinical Centers (...
Platform Delivery Technologies for Nucleic Acid Therapeutics (R41/R42)
Comparative Biology of Neurodegeneration (R21) is not endorsed by, or affiliated with, any government agency. Copyright ©2016